GX-19

GX-19

GX-19

Vaccine candidate against COVID-19

GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.[1][2][3][4]

Quick Facts Vaccine description, Target ...

It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.[5]

References

  1. [1]
    "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. United States National Library of Medicine. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  2. [2]
    "Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. 18 January 2021. Retrieved 16 March 2021.
  3. [3]
    "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  4. [4]
    "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.
  5. [5]
    Seo YB, Suh YS, Ryu JI, Jang H, Oh H, Koo BS, et al. (March 2021). "Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates". Vaccines. 9 (4): 307. doi:10.3390/vaccines9040307. PMC 8063950. PMID 33804981.
Scholia has a profile for GX-19 (Q106616276).
Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article GX-19, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.